Caplin Point Labs News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Caplin Point Laboratories Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Caplin Point Laboratories Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Caplin Point Labs from all sources in a single place.

Caplin Point Laboratories Ltd.

01 Jan 2026

1820.20

0.45%

Caplin Point strengthens US injectables, opthalmic segment with acquisition of 10 new ANDAs

Business Line

The addressable market of these products was $473.2 million for the 12-month period ending August 2025, the company said in its note to the exchanges

Caplin Point Laborat.. has an average target of 2397.00 from 2 brokers.

Caplin Point Laboratories Ltd.

01 Jan 2026

1820.20

0.45%

Company Update

Caplin Point Laboratories Ltd - 524742 - Intimation Of Press Release On Acquisition Of Andas

BSE India

Company had disseminated a press release containing information on acquisition of ten ANDAs from a Global generic manufacturing company.

pdf

Caplin Point Laboratories Ltd.

31 Dec 2025

1820.20

0.45%

SAST

Caplin Point Laboratories Ltd - 524742 - Closure of Trading Window

BSE India

Intimation of Closure of Trading window commencing from January 01, 2026.

pdf

Caplin Point Laboratories Ltd.

31 Dec 2025

1820.20

0.45%

AGM

Caplin Point Laboratories Ltd - 524742 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

BSE India

We enclose herewith the Notice of Postal Ballot of Caplin Point Laboratories Limited seeking the approval of members for the resolutions mentioned in the Notice.

pdf

Caplin Point Laboratories Ltd.

12 Dec 2025

1820.20

0.45%

Company Update

Caplin Point Laboratories Ltd - 524742 - Completion Of Inspection By INVIMA-Colombia At The Puducherry Injectables …

BSE India

This is to inform you that INVIMA - Colombia conducted an inspection of the injectables facility of the Company located at Puducherry. The inspection was conducted between 8th December 2025 and 12th December 2025 and was completed successfully.

pdf

Caplin Point Laboratories Ltd.

09 Dec 2025

1820.20

0.45%

Company Update

Caplin Point Laboratories Ltd - 524742 - Press Release On USFDA Approval

BSE India

Press Release on the company''s Subsidiary, Caplin Steriles Limited, getting USFDA approval for its ANDA Linezolid Injection 600 mg/ 300 mL (2 mg/mL) Single Dose Infusion Bags

pdf

Caplin Point Laboratories Ltd.

08 Dec 2025

1820.20

0.45%

Company Update

Caplin Point Laboratories Ltd - 524742 - Intimation Of Press Release

BSE India

Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited from USFDA for ANDA Acetaminophen Injection, 1000 mg/100 mL (10 mg/ mL) single dose infusion bags.

pdf

Caplin Point Laboratories Ltd.

14 Nov 2025

1820.20

0.45%

Company Update

Caplin Point Laboratories Ltd - 524742 - Acquisition Of Land By Subsidiary

BSE India

Acquisition of land by Subsidiary at Mexico

pdf

Caplin Point Laboratories Ltd.

12 Nov 2025

1820.20

0.45%

Earnings Call

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of the Earnings Call - Q2 & H1 FY 2025-26

pdf

Caplin Point Laboratories Ltd.

10 Nov 2025

1820.20

0.45%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Firm expansion plans in place- In the US, the company is optically transitioning to B2C model to focus on high margin products. The company is also looking for third party ANDAs (4 already acquired, 5 more to come) as well as outsourcing some in-house products to the CMOs for optimal plant utilisation. This, we believe is a part of larger strategy where the company wants to increase the offerings via front-end and at the same time focusing on margin expansion. The legacy LatAm growth was slower seemingly on account of some saturation in the existing markets and focus...

Caplin Point Laborat.. has an average target of 2397.00 from 2 brokers.

Is Caplin Point Laboratories Ltd. worth buying?

491 Votes:

Buy 80.86%

Sell 12.22%

Hold 6.92%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf